• Alebund Pharmaceuticals announced partner R1 Therapeutics presented AP306's Phase IIb trial design at ASN Kidney Week on Oct. 22, 2026.
• The jointly sponsored US-China study plans to enroll approximately 168 patients with hyperphosphatemia receiving maintenance hemodialysis.
• The placebo-controlled trial will assess the oral drug's phosphate-lowering effect, safety and tolerability over eight weeks.
• Researchers will compare twice-daily and three-times-daily dosing to guide further development and potentially reduce patients' medication burden.
• Enrollment is ongoing, with completion expected in the second quarter of 2027; topline results will be announced subsequently.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230700PR_NEWS_USPR_____CN79595) on October 23, 2026, and is solely responsible for the information contained therein.